Dulaglutide is one of the long-acting GLP-1 RAs administered as a once-weekly subcutaneous injection approved for the treatment of adults with T2DM in 2014, and it can be used as a monotherapy or in addition to an oral hypoglycemic or insulin therapy [16]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.